Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma
Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.
Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.
There is a clinical trial ongoing with bb2121, which is a CAR T-cell therapy against a B-cell maturation antigen (BCMA). This is an ongoing phase I dose-escalation study, states Jagannath. The results demonstrate the first 11 patients could be escalated further.
Overall, this has been well tolerated. Cytokine release syndrome was experienced but has only been shown to be of grade 1/2, states Jagannath.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
